In vivo RNAi delivery
Monday, 16 February, 2009
Invitrogen has launched its Invivofectamine delivery reagent, which enables siRNA experiments in vivo. As opposed to other offerings on the market, Invivofectamine delivery reagent can be injected in small volumes and without high pressure, minimising the potential of inconsistent results. It also provides extra stability to siRNA so the siRNA will arrive intact and ready to perform the selected knockdown. The reagent is non-viral and has minimal toxicity. Overall, these characteristics will enable researchers to more effectively optimize their siRNA experiments in vivo.
Invitrogen
www.invitrogen.com/invivornai
Potential biological targets for vascular dementia
Caused by damage to blood vessels in the brain, there is currently no approved treatment for...
Ecopha Biotech announces strategic cross-border model
To commercialise its ecopha.bio technology for a Pongamia-based bioeconomy, Australian company...
Could this 'virus-tearing' plastic film protect hospital equipment?
A thin plastic film that tears apart viruses on contact could help protect high-touch hospital...
